| Bioactivity | Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research[1][2]. |
| Invitro | Rilotumumab (10 μg/mL; overnight) shows the decrease of MET phosphorylation at Y1234 and Y1235, and an increase in total MET[2]. Western Blot Analysis[2] Cell Line: |
| In Vivo | Rilotumumab (intraperitoneal injection; 1.5 mg/kg; once two days; 11 d) treatment inhibits glioma cell growth in vivo[2]. Animal Model: |
| Name | Rilotumumab |
| CAS | 872514-65-3 |
| Appearance | Liquid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ryan CJ, et al. Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin Cancer Res. 2013 Jan 1;19(1):215-24. [2]. Greenall SA, et al. EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications. Oncogene. 2015 Oct 8;34(41):5277-87. |